During my time as CDC Director, I saw how quickly new substances can disrupt our public health systems. I need to highlight a pressing issue today: a potent synthetic opioid masquerading as natural kratom.
Having spent decades as a virologist studying how pathogens evolve, I see a similar trend with dangerous substances that learn to evade detection. The case of compound 7-hydroxymitraginine exemplifies how manufacturers exploit regulatory loopholes to create products resembling unregulated drugs.
Recent tests conducted by the Tampa Bay Times discovered Kratom tablets containing 15 milligrams of 7-hydroxymitraginine each, which experts equate to “legal morphine.” These aren’t just trace remnants typically found in Kratom leaf. Laboratory analyses confirm that these concentrations stem from chemical alterations made by manufacturers.
For context, natural kratom contains less than 0.01% 7-hydroxymitraginine, while these synthetic versions contain up to 150 times that amount. This isn’t the traditional plant-based kratom; it’s a pharmaceutical-grade opioid that’s unregulated.
In 2024, the FDA completed a clinical trial on ground kratom leaves with experienced users. The outcomes were enlightening. Participants showed no severe adverse effects at doses up to 12 grams, with only mild nausea noted. Importantly, “drug preference” scores didn’t significantly differ from placebo, suggesting a lower potential for abuse compared to natural leaf.
This clinical evidence provides a crucial scientific baseline. Historically, natural kratom leaves, when used appropriately, pose a different risk profile than the synthetic products saturating the American market today.
Yet, some manufacturers are misusing this FDA data to justify products that bear little resemblance to the ones actually studied. It’s a dangerous bait-and-switch, exploiting both regulatory gaps and consumer trust.
We don’t need to start from scratch; the bipartisan Kratom Consumer Protection and Safety Act of 2025 offers a scientifically sound framework to tackle this crisis. This law limits 7-hydroxymitraginine to 0.1% of total alkaloids—levels typical of natural kratom—while outright banning synthetic variants.
Moreover, the Department of Health and Human Services has the authority to act now. They can issue emergency import alerts for products exceeding natural alkaloid levels, classify 7-hydroxymitraginine as an unapproved drug for seizures, and work with the DEA to control synthetic analogs.
Having led the CDC during one of the opioid epidemic’s deadliest phases, I’ve learned that early intervention is paramount. The crisis surrounding synthetic opioids has made it clear that waiting for problems to escalate before acting is not effective—and quite futile.
The similarities are striking: products crafted to sidestep regulations, with unknown effectiveness, under minimal oversight. If we allow 7-hydroxymitraginine to follow a path similar to fentanyl, we could be responsible for more avoidable deaths.
This isn’t about banning kratom. When used responsibly, full-spectrum kratom appears safe based on the FDA’s clinical data, preventing synthetic opioids from hiding under plant-based labels.
I urge the FDA and HHS to respond with the urgency this situation demands. Each day we wait, more Americans are at risk from untested substances that carry unknown dangers.
The science is definitive. Regulatory mechanisms are in place. The real question is whether we will utilize them before another surge of synthetic opioid overdoses forces emergency responses nationwide.
We cannot let another generation of Americans fall victim to regulatory inaction. The time to act is now.
